These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 25669174)

  • 1. Altered morphine glucuronide and bile acid disposition in patients with nonalcoholic steatohepatitis.
    Ferslew BC; Johnston CK; Tsakalozou E; Bridges AS; Paine MF; Jia W; Stewart PW; Barritt AS; Brouwer KL
    Clin Pharmacol Ther; 2015 Apr; 97(4):419-27. PubMed ID: 25669174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population Pharmacokinetics of Morphine in Patients With Nonalcoholic Steatohepatitis (NASH) and Healthy Adults.
    Pierre V; Johnston CK; Ferslew BC; Brouwer K; Gonzalez D
    CPT Pharmacometrics Syst Pharmacol; 2017 May; 6(5):331-339. PubMed ID: 28417561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Physiologically-Based Pharmacokinetic Model of Morphine and Morphine-3-Glucuronide in Nonalcoholic Steatohepatitis.
    Sjöstedt N; Neuhoff S; Brouwer KLR
    Clin Pharmacol Ther; 2021 Mar; 109(3):676-687. PubMed ID: 32897538
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanistic basis of altered morphine disposition in nonalcoholic steatohepatitis.
    Dzierlenga AL; Clarke JD; Hargraves TL; Ainslie GR; Vanderah TW; Paine MF; Cherrington NJ
    J Pharmacol Exp Ther; 2015 Mar; 352(3):462-70. PubMed ID: 25512370
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Altered regulation of hepatic efflux transporters disrupts acetaminophen disposition in pediatric nonalcoholic steatohepatitis.
    Canet MJ; Merrell MD; Hardwick RN; Bataille AM; Campion SN; Ferreira DW; Xanthakos SA; Manautou JE; A-Kader HH; Erickson RP; Cherrington NJ
    Drug Metab Dispos; 2015 Jun; 43(6):829-35. PubMed ID: 25788542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the disposition of hepatically-generated morphine-3-glucuronide and morphine-6-glucuronide in isolated perfused liver from the guinea pig.
    Milne RW; Jensen RH; Larsen C; Evans AM; Nation RL
    Pharm Res; 1997 Aug; 14(8):1014-8. PubMed ID: 9279882
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Randomized, Crossover Study on the Effect of Food on the Pharmacokinetic Characteristics of Morphine ARER (MorphaBond™ ER), an Abuse-Deterrent Formulation of Extended-Release Morphine.
    Kinzler ER; Pantaleon C; Iverson M; Aigner S
    Adv Ther; 2019 Sep; 36(9):2394-2401. PubMed ID: 31278694
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Application of a loading wash-out method for investigating the hepatocellular efflux of a hepatically-generated metabolite, morphine-3-glucuronide.
    Evans AM; O'Brien J; Nation RL
    J Pharm Pharmacol; 1999 Nov; 51(11):1289-97. PubMed ID: 10632087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of bile acids in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Chow MD; Lee YH; Guo GL
    Mol Aspects Med; 2017 Aug; 56():34-44. PubMed ID: 28442273
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Altered Bile Acid Metabolome in Patients with Nonalcoholic Steatohepatitis.
    Ferslew BC; Xie G; Johnston CK; Su M; Stewart PW; Jia W; Brouwer KL; Barritt AS
    Dig Dis Sci; 2015 Nov; 60(11):3318-28. PubMed ID: 26138654
    [TBL] [Abstract][Full Text] [Related]  

  • 11. INT-767 improves histopathological features in a diet-induced
    Roth JD; Feigh M; Veidal SS; Fensholdt LK; Rigbolt KT; Hansen HH; Chen LC; Petitjean M; Friley W; Vrang N; Jelsing J; Young M
    World J Gastroenterol; 2018 Jan; 24(2):195-210. PubMed ID: 29375205
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Altered bile acid composition and disposition in a mouse model of non-alcoholic steatohepatitis.
    Suga T; Yamaguchi H; Ogura J; Shoji S; Maekawa M; Mano N
    Toxicol Appl Pharmacol; 2019 Sep; 379():114664. PubMed ID: 31306673
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum bile acid patterns are associated with the presence of NAFLD in twins, and dose-dependent changes with increase in fibrosis stage in patients with biopsy-proven NAFLD.
    Caussy C; Hsu C; Singh S; Bassirian S; Kolar J; Faulkner C; Sinha N; Bettencourt R; Gara N; Valasek MA; Schnabl B; Richards L; Brenner DA; Hofmann AF; Loomba R
    Aliment Pharmacol Ther; 2019 Jan; 49(2):183-193. PubMed ID: 30506692
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of morphine and its glucuronidated metabolites in burn injuries.
    Perreault S; Choinière M; du Souich PB; Bellavance F; Beauregard G
    Ann Pharmacother; 2001 Dec; 35(12):1588-92. PubMed ID: 11793627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The presence and severity of nonalcoholic steatohepatitis is associated with specific changes in circulating bile acids.
    Puri P; Daita K; Joyce A; Mirshahi F; Santhekadur PK; Cazanave S; Luketic VA; Siddiqui MS; Boyett S; Min HK; Kumar DP; Kohli R; Zhou H; Hylemon PB; Contos MJ; Idowu M; Sanyal AJ
    Hepatology; 2018 Feb; 67(2):534-548. PubMed ID: 28696585
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mice lacking multidrug resistance protein 3 show altered morphine pharmacokinetics and morphine-6-glucuronide antinociception.
    Zelcer N; van de Wetering K; Hillebrand M; Sarton E; Kuil A; Wielinga PR; Tephly T; Dahan A; Beijnen JH; Borst P
    Proc Natl Acad Sci U S A; 2005 May; 102(20):7274-9. PubMed ID: 15886284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bile Acid Alterations Are Associated With Insulin Resistance, but Not With NASH, in Obese Subjects.
    Legry V; Francque S; Haas JT; Verrijken A; Caron S; Chávez-Talavera O; Vallez E; Vonghia L; Dirinck E; Verhaegen A; Kouach M; Lestavel S; Lefebvre P; Van Gaal L; Tailleux A; Paumelle R; Staels B
    J Clin Endocrinol Metab; 2017 Oct; 102(10):3783-3794. PubMed ID: 28938455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ratio of Conjugated Chenodeoxycholic to Muricholic Acids is Associated with Severity of Nonalcoholic Steatohepatitis.
    Chen J; Zheng M; Liu J; Luo Y; Yang W; Yang J; Liu J; Zhou J; Xu C; Zhao F; Su M; Zang S; Shi J;
    Obesity (Silver Spring); 2019 Dec; 27(12):2055-2066. PubMed ID: 31657148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Pharmacokinetic Natural Product-Disease-Drug Interaction: A Double Hit of Silymarin and Nonalcoholic Steatohepatitis on Hepatic Transporters in a Rat Model.
    Montonye ML; Tian DD; Arman T; Lynch KD; Hagenbuch B; Paine MF; Clarke JD
    J Pharmacol Exp Ther; 2019 Nov; 371(2):385-393. PubMed ID: 31420525
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The pharmacokinetics of morphine and its glucuronide conjugate in a rat model of streptozotocin-induced diabetes and the expression of MRP2, MRP3 and UGT2B1 in the liver.
    Hasegawa Y; Kishimoto S; Shibatani N; Nomura H; Ishii Y; Onishi M; Inotsume N; Takeuchi Y; Fukushima S
    J Pharm Pharmacol; 2010 Mar; 62(3):310-4. PubMed ID: 20487213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.